NovaHep AB is a Swedish biotech company founded in 2005 as a spin-off from the Karolinska Institute. The company is run by venture capital from Sweden, Switzerland and South Korea. NovaHep masters a new and powerful technology in the field of advanced regenerative medicine. Using the patient’s own cells, a tissue, even though it comes from a different individual, will be recognized by the patient’s immune system as endogenous. The patented technology will primarily be used to replace failing blood vessels, and the company is expected to sell products and services on a vast market starting 2019. Products will also be developed in other areas of medicine, and NovaHep’s technology will be able to help millions of patients with serious diseases and saving huge societal values through fewer and shorter sick leave.